ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,495.20
0.56%
S&P ASX All Technology
4,017.00
1.28%
Brent Oil
73.535
2.29%
US Dollar vs AUD
1.5417
-0.18%
Bitcoin
95,169.77
-0.72%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AtriCure Inc (ATRC) Share Price

AtriCure Inc

AtriCure Inc (ATRC)

NASDAQ
36.47
-0.59
( -1.59% )
Updated: 06:13:16
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
36.47
Bid
36.45
Offer
36.49
Volume
200,526
35.76 Day's Range 37.04
18.94 52 Week Range 39.045
Market Cap
1.778B
Previous Close
37.06
Open
36.67
Last Trade
1
@
36.49
Last Trade Time
06:13:32
Financial Volume
US$ 7,291,727
VWAP
36.363
Average Volume (3m)
562,051
Shares Outstanding
48,753,251
Dividend Yield
-
PE Ratio
-58.47
Earnings Per Share (EPS)
-0.62
Revenue
399.25M
Net Profit
-30.44M

About AtriCure Inc

AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft T... AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.atricure.com
Headquarters
Wilmington, Delaware, USA
Founded
-
AtriCure Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker ATRC. The last closing price for AtriCure was US$37.06. Over the last year, AtriCure shares have traded in a share price range of US$ 18.94 to US$ 39.045.

AtriCure currently has 48,753,251 shares in issue. The market capitalisation of AtriCure is US$1.81 billion. AtriCure has a price to earnings ratio (PE ratio) of -58.47.

Ask ADVFN Intelligence (AI)

ATRC Latest News

More News

AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

21 November 2024
Business Wire

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

15 November 2024
Edgar (US Regulatory)

AtriCure to Participate in the Stifel 2024 Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

08 November 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

31 October 2024
Edgar (US Regulatory)

Form 8-K - Current report

30 October 2024
Edgar (US Regulatory)

AtriCure Reports Third Quarter 2024 Financial Results

Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year Achieved 20% growth on revenues from open appendage...

30 October 2024
Business Wire

AtriCure to Participate in the UBS Global Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

28 October 2024
Business Wire

AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

15 October 2024
Business Wire

AtriCure to Announce Third Quarter 2024 Financial Results

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain...

08 October 2024
Business Wire

AtriCure a obtenu la certification de marquage CE pour la pince EnCompass®

Une approbation qui sert de nouveau vecteur de croissance à l'international pour AtriCure AtriCure, Inc. ( Nasdaq: ATRC ), leader en matière d'innovation pour les interventions chirurgicales et...

02 October 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.3250.89915617651136.14537.3335.5635600636.37467285CS
42.918.6710369487533.5638.3433.4547893936.18565934CS
1210.2138.880426504226.2638.3425.9556205131.30155542CS
2613.256.725397507523.2738.3418.9471646125.97445612CS
52-0.23-0.62670299727536.739.04518.9469308827.71453821CS
156-31.61-46.430669800268.0874.84518.9443541536.62501432CS
2607.224.598565083729.2789.1818.9440110742.28799315CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CTNTCheetah Net Supply Chain Service Inc
US$ 5.31
(183.96%)
109.29M
ZJKZJK Industrial Company Ltd
US$ 14.6773
(131.50%)
20.82M
GWAVGreenwave Technology Solutions Inc
US$ 0.6193
(69.67%)
408.19M
JYDJayud Global Logistics Ltd
US$ 1.089
(62.51%)
9.49M
JANXJanux Therapeutics Inc
US$ 61.96
(54.21%)
5.78M
REVBRevelation Biosciences Inc
US$ 0.5798
(-38.96%)
3.96M
STSSSharps Technology Inc
US$ 2.14
(-36.19%)
392.46k
OMEXOdyssey Marine Exploration Inc
US$ 0.48005
(-35.58%)
3.61M
GELSGelteq Ltd
US$ 2.635
(-31.03%)
238.77k
TTGTTech Target Inc
US$ 22.01
(-30.22%)
155.99k
GWAVGreenwave Technology Solutions Inc
US$ 0.6193
(69.67%)
408.19M
SMCISuper Micro Computer Inc
US$ 41.28
(-1.71%)
172.69M
CTNTCheetah Net Supply Chain Service Inc
US$ 5.31
(183.96%)
109.29M
CHRSCoherus BioSciences Inc
US$ 1.86
(35.77%)
105.59M
NVDANVIDIA Corporation
US$ 139.12
(0.35%)
104.19M

ATRC Discussion

View Posts
mlkrborn mlkrborn 11 years ago
HISTORY
Initial Public Offering



On August 10, 2005, we consummated an initial public offering of 4.6 million shares of our common stock at $12.00 per share, which includes the underwriters exercise of their over-allotment option, on August 9, 2005, to purchase 600,000 shares of our common stock of which 450,000 shares were sold by selling shareholders and 150,000 shares were sold by us. We did not receive any proceeds from the sale of the 450,000 shares of common stock that were sold by selling shareholders. These share amounts reflect a 1-for-3.8 reverse split of our capital stock that was effected on July 27, 2005. Proceeds to us from the offering, after deducting underwriting discounts and commissions but before expenses, were $46.3 million. Expenses are estimated to be approximately $3.25 million.



15
👍️0
mlkrborn mlkrborn 11 years ago
AtriCure receives FDA approval for investigational study to evaluate stroke prevention in atrial fibrillation (ATRC) 14.35 : Co announces the FDA approval to begin enrollment in a clinical study of AtriCure's AtriClip Left Atrial Appendage Exclusion System. The study will evaluate the use of the AtriClip device to prevent stroke in patients with Afib. The feasibility study will enroll Afib patients at seven medical centers across the country. The study will focus on patients with risk factors that place them at significant risk of stroke as well as substantial bleeding risks that contraindicate them for anticoagulation therapy. Research suggests that up to 40% of patients are unable to take oral anticoagulants due to excessive risk of bleeding.
👍️0
dmarkg dmarkg 12 years ago
Hey Wobblenuts and Jackie Scan I want to show you something....

Medical Breakthrough Wound Stasis Technology

ATRC and EPGL could possibly go hand in hand here...
Merry Christmas 2012

Merry Chirstmas 2012, friends.
👍️0
wobblenuts wobblenuts 12 years ago
Any talks involving ATRC and soon to be sub penny wonder EPGL?



Are they hinting at something here?


1)"ATRC fully SEC reporting financials are available at OTCMARKETS for EPGL investors to see as an example of where EPGL management is headed."

2)"EPGL initiating R&D on 4 new medical devices before end of 2012."

3)"Property and equipment, net 0"
👍️0
Penny Roger$ Penny Roger$ 13 years ago
~ Monday! $ATRC ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $ATRC ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=ATRC&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=ATRC&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=ATRC
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=ATRC#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=ATRC+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=ATRC
Finviz: http://finviz.com/quote.ashx?t=ATRC
~ BusyStock: http://busystock.com/i.php?s=ATRC&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=ATRC >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.
👍️0
Penny Roger$ Penny Roger$ 13 years ago
AtriCure, Inc., is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues, is Isolator Synergy bipolar ablation clamp system (Isolator system) and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage.

http://www.google.com/finance?q=ATRC
👍️0

Your Recent History

NASDAQ
ATRC
AtriCure
DOWI
DJDXAHUT
DJ Developed Markets ExA...
DOWI
DJUSDN
DJ US Defense
EU
ALSGD
Spineguard
BIT
BIRO
Estrima
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved